1. Articles from ncbi.nlm.nih.gov

  2. 1513-1536 of 1715 « 1 2 ... 61 62 63 64 65 66 67 ... 70 71 72 »
    1. Deoxyhypusine synthase (DHPS) inhibitor GC7 induces p21/Rb-mediated inhibition of tumor cell growth and DHPS expression correlates with poor prognosis in neuroblastoma patients.

      Deoxyhypusine synthase (DHPS) inhibitor GC7 induces p21/Rb-mediated inhibition of tumor cell growth and DHPS expression correlates with poor prognosis in neuroblastoma patients.

      Cell Oncol (Dordr). 2014 Oct 15;

      Authors: Bandino A, Geerts D, Koster J, Bachmann AS

      Read Full Article
    2. Serum Neuron-specific Enolase Levels in Preterm and Term Newborns and in Infants 1-3 Months of Age.

      Serum Neuron-specific Enolase Levels in Preterm and Term Newborns and in Infants 1-3 Months of Age.

      Pediatr Neonatol. 2014 Oct 11;

      Authors: Abbasoglu A, Sarialioglu F, Yazici N, Bayraktar N, Haberal A, Erbay A

      Abstract BACKGROUND: Elevated serum levels of neuron-specific enolase (NSE) was initially assumed to be specific to neuronal tumors (particularly neuroblastoma), but is now known to accompany nontumoral conditions and tumors other than neuroblastomas.

      Read Full Article
      Mentions: Diagnostics
    3. Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients.

      Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients.

      Genome Med. 2014;6(9):69

      Authors: Scollon S, Bergstrom K, Kerstein RA, Wang T, Hilsenbeck SG, Ramamurthy U, Gibbs RA, Eng CM, Chintagumpala MM, Berg SL, McCullough LB, McGuire AL, Plon SE, Parsons DW

      Read Full Article
      Mentions: Diagnostics
    4. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia.

      Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia.

      N Engl J Med. 2014 Oct 16;371(16):1507-1517

      Authors: Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA

      Read Full Article
      Mentions: T-Cells
    5. Regulation by miR181 Family of the Dependence Receptor CDON Tumor Suppressive Activity in Neuroblastoma.

      Regulation by miR181 Family of the Dependence Receptor CDON Tumor Suppressive Activity in Neuroblastoma.

      J Natl Cancer Inst. 2014 Nov;106(11)

      Authors: Gibert B, Delloye-Bourgeois C, Gattolliat CH, Meurette O, Le Guernevel S, Fombonne J, Ducarouge B, Lavial F, Bouhallier F, Creveaux M, Negulescu AM, Bénard J, Janoueix-Lerosey I, Harel-Bellan A, Delattre O, Mehlen P

      Read Full Article
    6. [The Role of MicroRNAs in the Pathophysiology of Neuroblastoma and Their Possible Use in Dia-gnosis, Prognosis and Therapy].

      [The Role of MicroRNAs in the Pathophysiology of Neuroblastoma and Their Possible Use in Dia-gnosis, Prognosis and Therapy].

      Klin Onkol. 2014;27(5):331-9

      Authors: Vinklárek J, Novák J, Bienertová-Vašků J, Stěrba J, Slabý O

      Abstract Neuroblastoma (NBL) is a typical childhood tumor developing from the precursor cells of the sympathetic nervous tissue and accounting for approximately 7% of total malignancies in pediatrics and 15% of deaths associated with this malignancy.

      Read Full Article
    7. Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation.

      Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation.

      Pediatr Blood Cancer. 2014 Oct 12;

      Authors: Umeda K, Adachi S, Tanaka S, Ogawa A, Hatakeyama N, Kudo K, Sakata N, Igarashi S, Ohshima K, Hyakuna N, Chin M, Goto H, Takahashi Y, Azuma E, Koh K, Sawada A, Kato K, Inoue M, Atsuta Y, Takami A, Murata M, on behalf of the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation

      Abstract BACKGROUND: Cyclosporine A (CsA) is used widely for graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation ...

      Read Full Article
    8. Challenges in managing infections among pediatric cancer patients: Suboptimal national essential medicines lists for low and middle income countries.

      Challenges in managing infections among pediatric cancer patients: Suboptimal national essential medicines lists for low and middle income countries.

      Pediatr Blood Cancer. 2014 Oct 12;

      Authors: Kirby J, Ojha RP, Johnson KM, Bittner EC, Caniza MA

      Abstract Infection management for pediatric cancer patients may be compromised in low and middle income countries (LMICs) if key antimicrobials are not included in national essential medicines lists.

      Read Full Article
    9. Phase I trial of seneca valley virus (NTX-010) in children with relapsed/refractory solid tumors: A report of the children's oncology group.

      Phase I trial of seneca valley virus (NTX-010) in children with relapsed/refractory solid tumors: A report of the children's oncology group.

      Pediatr Blood Cancer. 2014 Oct 12;

      Authors: Burke MJ, Ahern C, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt MB, Blaney SM

      Read Full Article
    10. Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.

      Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.

      Pediatr Blood Cancer. 2014 Oct 12;

      Authors: Hanmod SS, Wang G, Edwards H, Buck SA, Ge Y, Taub JW, Wang Z

      Abstract BACKGROUND: Despite advances in treatment regimens, patients with high-risk neuroblastoma have long-term survival rates of < 40%. Wee1 inhibition in combination with CHK1 inhibition has shown promising results in neuroblastoma cells.

      Read Full Article
    11. Refinement of treatment strategies in ex vivo T-cell-depleted haploidentical SCT for pediatric patients.

      Refinement of treatment strategies in ex vivo T-cell-depleted haploidentical SCT for pediatric patients.

      Bone Marrow Transplant. 2014 Oct 13;

      Authors: Im HJ, Koh KN, Suh JK, Lee SW, Choi ES, Jang S, Kwon SW, Park CJ, Seo JJ

      Abstract We evaluated the feasibility of T-cell-depleted haploidentical hematopoietic SCT (HHCT) in pediatric patients.

      Read Full Article
    12. The communication of the radiation risk from CT in relation to its clinical benefit in the era of personalized medicine : Part 2: benefits versus risk of CT.

      "Proper documentation of the informed decision process is important for future reference. In concert with our referring physicians, pediatric radiologists are well-equipped to tackle the complexities associated with the communication of CT risk, a task that often falls upon us, and by becoming more involved in the diagnostic decision process we can add value to the health care system."

      Read Full Article
    13. The communication of the radiation risk from CT in relation to its clinical benefit in the era of personalized medicine : Part 1: the radiation risk from CT.

      "Most authorities now conclude that there is enough evidence to link future cancers to the radiation exposure from a single CT scan in childhood but that cancer risk estimates for individuals must be based on the specifics of exposure, age at exposure and absorbed dose to certain tissues. Generalizations are not appropriate, and the communication of the CT risk to individuals should be conducted within the framework of personalized medicine."

      Read Full Article
    14. Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.

      "Multiple phosphorylated peptides from downstream mediators of the PI3K/AKT/mTOR and RAS pathways were also highly abundant in NB10 relative to NPC. Our analysis highlights the importance of RET, IGF-1R/IR and FGFR1 as RTKs in neuroblastoma and suggests a methodology that can be used to identify potential novel biological therapeutic targets. Furthermore, application of this previously unexploited technology in the clinic opens the possibility of providing a new wide-scale molecular signature to assess disease progression and prognosis."

      Read Full Article
    15. Aurora kinase A is superior to Ki67 as a prognostic indicator of survival in neuroblastoma.

      "High AURKA and Ki67 levels were significantly associated with shorter overall survival (OS) and event-free survival (EFS) in univariate analyses. In multivariate analyses, high AURKA level was associated with significantly shorter OS and EFS, independently of risk group, and of MYCN amplification and MKI. High Ki67 level was not associated with shorter OS or EFS after adjustment for risk group or MYCN amplification and MKI."

      Read Full Article
      Mentions: MYCN
    16. Pattern of malignant solid tumors and lymphomas in children in the east delta of Egypt: A five-year study.

      Egypt: "The survival rate was significantly higher in patients with Wilm's tumor and Hodgkin lymphoma, followed by NHL (92.0, 88.0 and 72.0%, respectively; P<0.001), while the mortality rate was significantly higher in patients with neuroblastoma (P<0.001). In conclusion, NHL and neuroblastoma were the most common tumors; the survival rates were higher in patients with Wilm's tumor and Hodgkin lymphoma and lower in patients with neuroblastoma. A larger multicenter study is required to further investigate the conclusions drawn from this study."

      Read Full Article
    17. Endocrinopathies in survivors of childhood neoplasia.

      "Advancements in cancer treatments have increased the number of survivors of childhood cancers. Endocrinopathies are common complications following cancer therapy and may occur decades later. The objective of the current review is to address the main endocrine abnormalities detected in childhood cancer survivors including disorders of the hypothalamic-pituitary axis, thyroid, puberty, gonads, bone, body composition, and glucose metabolism."

      Read Full Article
    18. Robust Selection of Cancer Survival Signatures from High-Throughput Genomic Data Using Two-Fold Subsampling.

      "Our method was evaluated on microarray data sets from neuroblastoma, lung adenocarcinoma, and breast cancer patients, extracting robust and relevant signatures for predicting survival risk. Signatures obtained by our method achieved high prediction performance and robustness, consistently over the three data sets. Genes with high selection probability in our robust signatures have been reported as cancer-relevant. The ordering of predictor coefficients associated with signatures was well-preserved across multiple trials of RS-PL, demonstrating the capability of our method for identifying a transferable consensus signature. The software is available as an R package rsig at CRAN (http://cran.r-project.org)."

      Read Full Article
    19. Olfactory neuroblastoma with focal ganglioneuroblastic differentiation: a case report with literature review.

      "Neuroblastomas, occurring in the nasal cavity, in analogy to other sites, tend to have an aggressive biologic behaviour and can histologically mimic other undifferentiated malignant neoplasms of the sinonasal tract. Differential diagnostic problems are discussed; a comprehensive review of the literature has also been performed with a focus on survival."

      Read Full Article
    20. MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation.

      "The majority of MYCN-targeting miRNAs in neuroblastoma showed a decrease in expression during murine MYCN-driven neuroblastoma tumor development. Therefore, we provide evidence that MYCN-targeting miRNAs are preferentially downregulated in MYCN-driven neuroblastoma, suggesting that MYCN negatively controls the expression of these miRNAs, to safeguard its expression."

      Read Full Article
      Mentions: MYCN
    21. Cerebellar and cortical abnormalities in paediatric opsoclonus-myoclonus syndrome.

      "Whole-brain analysis indicated that cerebellar grey matter was significantly reduced in the patients with OMS, particularly in the vermis and flocculonodular lobe. A region-of-interest analysis indicated significantly lower cerebellar grey matter volume, particularly in patients with the greatest OMS scores. Diffusion-weighted images did not show effects at a whole brain level, but all major cerebellar tracts showed increased mean diffusivity when analysis was restricted to the cerebellum. Cortical thickness was reduced across the motor and visual areas in the OMS group, indicating involvement beyond the cerebellum."

      Read Full Article
    1513-1536 of 1715 « 1 2 ... 61 62 63 64 65 66 67 ... 70 71 72 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video